Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

H3K79 methylation profiles define murine and human MLL-AF4 leukemias.

Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, Kutok JL, Kung AL, Armstrong SA.

Cancer Cell. 2008 Nov 4;14(5):355-68. doi: 10.1016/j.ccr.2008.10.001.

2.

Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.

Chen CW, Armstrong SA.

Exp Hematol. 2015 Aug;43(8):673-84. doi: 10.1016/j.exphem.2015.05.012. Review.

3.

MLL leukemia and future treatment strategies.

Marschalek R.

Arch Pharm (Weinheim). 2015 Apr;348(4):221-8. doi: 10.1002/ardp.201400449. Review.

PMID:
25740345
4.

Targeting epigenetic programs in MLL-rearranged leukemias.

Bernt KM, Armstrong SA.

Hematology Am Soc Hematol Educ Program. 2011;2011:354-60. doi: 10.1182/asheducation-2011.1.354. Review.

PMID:
22160057
5.

Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement.

Bueno C, Montes R, Catalina P, Rodríguez R, Menendez P.

Leukemia. 2011 Mar;25(3):400-10. doi: 10.1038/leu.2010.284. Review.

PMID:
21135858
6.

MLL translocations, histone modifications and leukaemia stem-cell development.

Krivtsov AV, Armstrong SA.

Nat Rev Cancer. 2007 Nov;7(11):823-33. Review.

PMID:
17957188
7.

Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.

Sanjuan-Pla A, Bueno C, Prieto C, Acha P, Stam RW, Marschalek R, Menéndez P.

Blood. 2015 Dec 17;126(25):2676-85. doi: 10.1182/blood-2015-09-667378. Review.

8.

A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.

Anglin JL, Song Y.

J Med Chem. 2013 Nov 27;56(22):8972-83. doi: 10.1021/jm4007752. Review.

9.

The molecular biology of mixed lineage leukemia.

Slany RK.

Haematologica. 2009 Jul;94(7):984-93. doi: 10.3324/haematol.2008.002436. Review.

10.

The emerging roles of DOT1L in leukemia and normal development.

McLean CM, Karemaker ID, van Leeuwen F.

Leukemia. 2014 Nov;28(11):2131-8. doi: 10.1038/leu.2014.169. Review.

PMID:
24854991
11.

The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle.

Kim W, Choi M, Kim JE.

Cell Cycle. 2014;13(5):726-38. doi: 10.4161/cc.28104. Review.

12.

The upstreams and downstreams of H3K79 methylation by DOT1L.

Vlaming H, van Leeuwen F.

Chromosoma. 2016 Sep;125(4):593-605. doi: 10.1007/s00412-015-0570-5. Review.

PMID:
26728620
13.

Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

Deshpande AJ, Bradner J, Armstrong SA.

Trends Immunol. 2012 Nov;33(11):563-70. doi: 10.1016/j.it.2012.06.002. Review.

14.

Genetically engineered mouse models of human B-cell precursor leukemias.

Hauer J, Borkhardt A, Sánchez-García I, Cobaleda C.

Cell Cycle. 2014;13(18):2836-46. doi: 10.4161/15384101.2014.949137. Review.

15.

SET/MLL family proteins in hematopoiesis and leukemia.

Yang W, Ernst P.

Int J Hematol. 2017 Jan;105(1):7-16. doi: 10.1007/s12185-016-2118-8. Review.

PMID:
27796741
16.

Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins.

Ballabio E, Milne TA.

Mol Cell Oncol. 2014 Oct 29;1(2):e955330. doi: 10.1080/23723548.2014.955330. Review.

Supplemental Content

Support Center